Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Article
  • Published:

GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity

Gene Therapy volume 12, pages 1033–1041 (2005)Cite this article

Abstract

The role of gap junctional intercellular communication (GJIC) in bystander killing with herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir (GCV) was evaluated in U251 cells expressing a dominant-negative connexin 43 cDNA (DN14), and in HeLa cells, reportedly devoid of connexin protein. These cell lines both exhibited 0% GJIC when assayed by Lucifer Yellow fluorescent dye microinjection. Bystander cytotoxicity was still apparent in 50:50 cocultures of DN14 and HSV-TK-expressing U251 cells, but not in 50:50 cocultures of HeLa cells. However, the sensitivity of HeLa HSV-TK-expressing cells to GCV decreased nearly 100-fold (IC90=109 μM) when cocultured with bystander cells compared to results in 100% cultures of HSV-TK-expressing cells (IC90=1.2 μM). A more sensitive flow cytometry technique to measure GJIC over 24 h revealed that the DN14 and HeLa cells exhibited detectable levels of communication (29 and 23%, respectively). Transfer of phosphorylated GCV to HeLa bystander cells occurred within 4 h after drug addition, and GCV triphosphate (GCVTP) accumulated to 213±84 pmol/106 cells after 24 h. In addition, GCVTP levels were decreased in HSV-TK-expressing cells in coculture (867±33 pmol/106 cells) compared to 100% cultures of HSV-TK-expressing cells (1773±188 pmol/106 cells). The half-life of GCVTP in the HSV-TK-expressing cells was approximately four times that measured in the bystander cells (12.3 and 3.1 h, respectively). These data suggest that the lack of bystander cytotoxicity in HeLa cocultures is due to low transfer of phosphorylated GCV and a rapid half-life of GCVTP in the bystander cells. Thus, GCV phosphate transfer to non-HSV-TK-expressing bystander cells may mediate either bystander cell killing or sparing of HSV-TK-positive cells, depending upon the cell specific drug metabolism.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8

Similar content being viewed by others

References

  1. Moolten FL . Drug sensitivity (suicide) genes for selective cancer chemotherapy. Cancer Gene Ther 1994; 1: 279–287.

    CAS  PubMed  Google Scholar 

  2. Yazama K, Fisher WE, Brunicardi FC . Current progress in suicide gene therapy for cancer. World J Surg 2002; 26: 783–789.

    Article  Google Scholar 

  3. Greco O, Dachs GU . Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. J Cell Physiol 2001; 187: 22–36.

    Article  CAS  PubMed  Google Scholar 

  4. Moolten FL . Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276–5281.

    CAS  PubMed  Google Scholar 

  5. Culver KW et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992; 256: 1550–1552.

    Article  CAS  PubMed  Google Scholar 

  6. Shewach DS et al. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. Cancer Gene Ther 1994; 1: 107–112.

    CAS  PubMed  Google Scholar 

  7. Moolten FL, Wells JM . Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Nat Cancer Inst 1990; 82: 297–300.

    Article  CAS  PubMed  Google Scholar 

  8. Boucher PD, Ruch RJ, Shewach DS . Differential ganciclovir-mediated cytotoxicity and bystander killing in human colon carcinoma cell lines expressing herpes simplex virus thymidine kinase. Human Gene Ther 1998; 9: 801–814.

    Article  CAS  Google Scholar 

  9. Rubsam LZ, Davidson BL, Shewach DS . Superior cytotoxicity with ganciclovir compared with acyclovir and 1-β-D-arabinofuranosylthymine in herpes simplex virus-thymidine kinase-expressing cells: a novel paradigm for cell killing. Cancer Res 1998; 58: 3873–3882.

    CAS  PubMed  Google Scholar 

  10. Ishii-Morita H et al. Mechanism of ‘bystander effect’ killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Therapy 1997; 4: 244–251.

    Article  CAS  PubMed  Google Scholar 

  11. Boucher PD, Ostruszka LJ, Murphy PJ, Shewach DS . Hydroxy-urea significantly enhances tumor growth delay in vivo with herpes simplex virus thymidine kinase/ganciclovir gene therapy. Gene Therapy 2002; 9: 1023–1030.

    Article  CAS  PubMed  Google Scholar 

  12. Smee DF et al. Intracellular metabolism and enzymatic phosphorylation of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus-infected and uninfected cells. Biochem Pharmacol 1985; 34: 1049–1056.

    Article  CAS  PubMed  Google Scholar 

  13. Biron KK et al. Metabolic activation of the nucleoside analog 9-{[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl}guanine in human diploid fibroblasts infected with human cytomegalovirus. Proc Nat Acad Sci USA 1985; 82: 2473–2477.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Cheng Y et al. Metabolism of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, a new anti-herpes compound, in herpes simplex virus-infected cells. J Biol Chem 1983; 258: 12460–12464.

    CAS  PubMed  Google Scholar 

  15. Keller PM et al. Enzymatic phosphorylation of acyclic nucleoside analogs and correlations with antiherpetic activities. Biochem Pharmacol 1981; 39: 3071–3077.

    Article  Google Scholar 

  16. Chen MS, Walker J, Prusoff WH . Kinetic studies of herpes simplex virus type 1-encoded thymidine and thymidylate kinase, a multifunctional enzyme. J Biol Chem 1979; 254: 10747–10753.

    CAS  PubMed  Google Scholar 

  17. Boehme RE . Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate kinase isozymes. J Biol Chem 1984; 259: 12346–12349.

    CAS  PubMed  Google Scholar 

  18. Balzarini J, Bohman C, De Clercq E . Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem 1993; 268: 6332–6337.

    CAS  PubMed  Google Scholar 

  19. Ilsley DD, Lee S, Miller WH, Kuchta RD . Acyclic guanosine analogs inhibit DNA polymerase α, δ, ɛ with very different potencies and have unique mechanisms of action. Biochemistry 1995; 34: 2504–2510.

    Article  CAS  PubMed  Google Scholar 

  20. Reardon JE . Herpes simplex virus type 1 and human DNA polymerase interactions with 2′-deoxyguanosine 5′-triphosphate analogs. J Biol Chem 1989; 264: 19039–19044.

    CAS  PubMed  Google Scholar 

  21. Reid R, Mar E, Huang E, Topal MD . Insertion and extension of acyclic, dideoxy, and ara nucleotides by herpesviridae, human α and β polymerases. J Biol Chem 1988; 263: 3898–3904.

    CAS  PubMed  Google Scholar 

  22. Roth JA, Cristiano RJ . Gene therapy for cancer: what have we done and where are we going? J Nat Cancer Ins 1997; 89: 21–39.

    Article  CAS  Google Scholar 

  23. Freytag SO et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002; 62: 4968–4976.

    CAS  PubMed  Google Scholar 

  24. Dewey RA et al. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nat Med 1999; 5: 1256–1263.

    Article  CAS  PubMed  Google Scholar 

  25. Floeth FW et al. Local inflammation and devascularization – in vivo mechanisms of the ‘bystander effect’ in VPC-mediated HSV-Tk/GCV gene therapy for human malignant glioma. Cancer Gene Ther 2001; 8: 843–851.

    Article  CAS  PubMed  Google Scholar 

  26. Pope IM, Poston GJ, Kinsella AR . The role of the bystander effect in suicide gene therapy. Eur J Cancer 1997; 33: 1005–1016.

    Article  CAS  PubMed  Google Scholar 

  27. Freeman SM et al. The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993; 53: 5274–5283.

    CAS  PubMed  Google Scholar 

  28. Princen F et al. A cell type-specific and gap junction-independent mechanism for the herpes simplex virus-1 thymidine kinase gene/ganciclovir-mediated bystander effect. Clin Cancer Res 1999; 5: 3639–3644.

    CAS  PubMed  Google Scholar 

  29. Rubsam LZ et al. Cytotoxicity and accumulation of ganciclovir triphosphate in bystander cells cocultured with herpes simplex virus type 1 thymidine kinase-expressing human glioblastoma cells. Cancer Res 1999; 59: 669–675.

    CAS  PubMed  Google Scholar 

  30. Mesnil M et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Nat Acad Sci 1996; 93: 1831–1835.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Mesnil M, Yamasaki H . Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res 2000; 60: 3989–3999.

    CAS  PubMed  Google Scholar 

  32. Tanaka T, Yamasaki H, Mesnil M . Stimulation of intercellular communication of poor-communicating cells by gap-junction-competent cells enhances the HSV-TK/GCV bystander effect in vitro. Int J Cancer 2001; 91: 538–542.

    Article  CAS  PubMed  Google Scholar 

  33. Mesnil M, Piccoli C, Yamasaki H . A tumor suppressor gene, Cx26, also mediates the bystander effect in HeLa cells. Cancer Res 1997; 57: 2929–2932.

    CAS  PubMed  Google Scholar 

  34. Touraine RL, Ishii-Morita H, Ramsey WJ, Blaese RM . The bystander effect in the HSVtk/ganciclovir system and its relationship to gap junctional communication. Gene Therapy 1998; 5: 1705–1711.

    Article  CAS  PubMed  Google Scholar 

  35. Asklund T et al. Gap junction-mediated bystander effect in primary cultures of human malignant gliomas with recombinant expression of the HSVtk gene. Exp Cell Res 2003; 284: 185–195.

    Article  CAS  PubMed  Google Scholar 

  36. Imaizumi K et al. Bystander tumoricidal effect and gap junctional communication in lung cancer cell lines. Am J Respiratory Cell Mol Bio 1998; 18: 205–212.

    Article  CAS  Google Scholar 

  37. Denning C, Pitts JD . Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Human Gene Ther 1997; 8: 1825–1835.

    Article  CAS  Google Scholar 

  38. Nicholas TW, Read SB, Burrows FJ, Kruse CA . Suicide gene therapy with herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects. Histol Histopathol 2003; 18: 495–507.

    CAS  PubMed  Google Scholar 

  39. Huang R et al. Connexin 43 (CX43) enhances chemotherapy-induced apoptosis in human glioblastoma cells. Int J Cancer 2001; 92: 130–138.

    Article  CAS  PubMed  Google Scholar 

  40. Goodenough DA, Goliger JA, Paul DL . Connexins, connexons, and intercellular communication. Annu Rev Biochem 1996; 65: 475–502.

    Article  CAS  PubMed  Google Scholar 

  41. Simon AM, Goodenough DA . Diverse functions of vertebrate gap junctions. Trends Cell Biol 1998; 8: 477–483.

    Article  CAS  PubMed  Google Scholar 

  42. Yeager M, Nicholson BJ . Structure of gap junction intercellular channels. Curr Opin Struct Biol 1996; 6: 183–192.

    Article  CAS  PubMed  Google Scholar 

  43. Ahmad S, Martin PEM, Evans WH . Assembly of gap junction channels. Eur J Biochem 2001; 268: 4544–4552.

    Article  CAS  PubMed  Google Scholar 

  44. Boucher PD, Ostruszka LJ, Shewach DS . Synergistic enhancement of herpes simplex virus thymidine kinase/ganciclovir-mediated cytotoxicity by hydroxyurea. Cancer Res 2000; 60: 1631–1636.

    CAS  PubMed  Google Scholar 

  45. Krutovskikh VA, Yamasaki H, Asamoto M . Inhibition of intrinsic gap-junction intercellular communication and enhancement of tumorigenicity of the rat bladder carcinoma cell line BC31 by a dominant-negative connexin 43 mutant. Mol Carcinogen 1998; 23: 254–261.

    Article  CAS  Google Scholar 

  46. Tomasetto C et al. Specificity of gap junction communication among human mammary cells and connexin transfectants in culture. J Cell Biol 1993; 122: 157–167.

    Article  CAS  PubMed  Google Scholar 

  47. Ruch RJ et al. Loss of gap junctions from DDT-treated rat liver epithelial cells. Carcinogenesis 1994; 15: 301–306.

    Article  CAS  PubMed  Google Scholar 

  48. Czyz J et al. Gap-junctional coupling measured by flow cytometry. Exp Cell Res 2000; 255: 40–46.

    Article  CAS  PubMed  Google Scholar 

  49. King TJ et al. Correlation between growth control, neoplastic potential and endogenous connexin43 expression in HeLa cell lines: implications for tumor progression. Carcinogenesis 2000; 21: 311–315.

    Article  CAS  PubMed  Google Scholar 

  50. Wygoda MR et al. Protection of herpes simplex virus thymidine kinase-transduced cells from ganciclovir-mediated cytotoxicity by bystander cells. Cancer Res 1997; 57: 1699–1703.

    CAS  PubMed  Google Scholar 

  51. Tsien RY . A non-disruptive technique for loading calcium buffers and indicators into cells. Nature 1981; 290: 527–528.

    Article  CAS  PubMed  Google Scholar 

  52. Oh DJ, Lee GM, Francis K, Palsson BO . Phototoxicity of the fluorescent membrane dyes PKH2 and PKH26 on the human hematopoietic KG1a progenitor cell line. Cytometry 1999; 36: 312–318.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the Pharmaceutical Science Training Program, Grant GM07767 from the National Institute of General Medical Sciences (NIGMS), Grant CA76581 from the NIH, and the University of Michigan Core Flow Cytometry Facility.

Author information

Authors and Affiliations

  1. Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, Michigan, USA

    B G Gentry, M Im, P D Boucher & D S Shewach

  2. Department of Pathology, Medical College of Ohio, Toledo, OH, USA

    R J Ruch

Authors
  1. B G Gentry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Im
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P D Boucher
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R J Ruch
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D S Shewach
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gentry, B., Im, M., Boucher, P. et al. GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity. Gene Ther 12, 1033–1041 (2005). https://doi.org/10.1038/sj.gt.3302487

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.gt.3302487

Keywords

This article is cited by

Search

Advanced search

Quick links